ProShare Advisors
OREX

ProShare Advisors’s Orexigen Therapeutics, Inc. OREX Stock Holding History

ProShare Advisors’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-10,836
Closed -$47K – 1588
2016
Q2 		$47K Sell
10,836
-1,112
-9% -$5.03K ﹤0.01% 1554
2016
Q1 		$67K Sell
11,948
-1,238
-9% -$16.1K ﹤0.01% 1542
2015
Q4 		$227K Buy
13,186
+2,646
+25% +$63.1K ﹤0.01% 1468
2015
Q3 		$222K Sell
10,540
-757
-7% -$25.9K ﹤0.01% 1272
2015
Q2 		$559K Sell
11,297
-1,039
-8% -$62.1K 0.01% 1055
2015
Q1 		$966K Buy
12,336
+1,548
+14% +$96K 0.01% 861
2014
Q4 		$654K Sell
10,788
-394
-4% -$19.8K 0.01% 1079
2014
Q3 		$476K Sell
11,182
-1,549
-12% -$83.2K 0.01% 1448
2014
Q2 		$787K Sell
12,731
-5,292
-29% -$308K 0.01% 1290
2014
Q1 		$1.17M Buy
18,023
+12,818
+246% +$867K 0.01% 1171
2013
Q4 		$293K Sell
5,205
-4,250
-45% -$239K ﹤0.01% 1167
2013
Q3 		$581K Buy
9,455
+2,286
+32% +$155K 0.01% 1335
2013
Q2 		$419K Buy
+7,169
New +$441K 0.01% 1466

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

ProShare Advisors's OREX Position: Q3 2016 in Review

ProShare Advisors sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2016, closing a stake of 10,836 shares — an estimated $47K sold.

ProShare Advisors first reported a position in OREX in Q2 2013 and held it in 13 quarters. The position peaked at $1.17M in Q1 2014. 55 funds tracked by Wall St. Rank hold OREX as of Q3 2016.

  • ProShare Advisors reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
  • ProShare Advisors sold 10,836 Orexigen Therapeutics, Inc. shares in Q3 2016, an estimated $47K.
  • ProShare Advisors first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 13 quarters.
  • ProShare Advisors's Orexigen Therapeutics, Inc. position peaked at $1.17M in Q1 2014.
  • 55 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2016.

Based on ProShare Advisors's 13F filing for Q3 2016, filed 10 Nov 2016.